Hypofractionation in glioblastoma multiforme

被引:65
|
作者
Hulshof, MCCM
Schimmel, EC
Bosch, DA
González, DG
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1100 DE Amsterdam, Netherlands
关键词
glioblastoma multiforme; radiotherapy; hypofractionation;
D O I
10.1016/S0167-8140(99)00183-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare conventional fractionation with hypofractionation in patients with a glioblastoma multiforme. Endpoints of the analysis are overall survival and palliative effect. Materials and methods: From 1988 to 1998, 155 patients with pathologically confirmed glioblastoma multiforme were prospectively analysed. Patients without irradiation and patients receiving an interstitial boost were excluded from this analysis. Three different radiation schemes were used in subsequent periods; 33 x 2, 8 x 5 and 4 x 7 Gy. In the last 5 years a scheme of 4 x 7 Gy conformal irradiation was given to poor prognosis patients. The more favourable group received the conventionally fractionated scheme up to 66 Gy. Results: Median survival was 7, 5.6 and 6.6 months for the 33 x 2, 8 x 5 and 4 x 7 Gy, respectively. In general, patients in the hypofractionation group had far worse prognostic factors compared with patients treated with the conventional scheme. The period of neurological improvement or stabilisation was similar between the 4 x 7 and 33 x 2 Gy group. Conclusion: An extreme hypofractionation scheme of 4 x 7 Gy conformal irradiation in poor prognostic glioblastoma patients is well tolerated, convenient for the patient and provides equal palliation without negative effects on survival compared with conventional fractionation. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [1] New Hypofractionation Radiation Strategies for Glioblastoma
    Melissa Azoulay
    Jennifer Shah
    Erqi Pollom
    Scott G. Soltys
    Current Oncology Reports, 2017, 19
  • [2] New Hypofractionation Radiation Strategies for Glioblastoma
    Azoulay, Melissa
    Shah, Jennifer
    Pollom, Erqi
    Soltys, Scott G.
    CURRENT ONCOLOGY REPORTS, 2017, 19 (09)
  • [3] Bevacizumab in glioblastoma multiforme
    Specenier, Pol
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (01) : 9 - 18
  • [4] Treatment of unresectable glioblastoma multiforme
    Nieder, C
    Grosu, AL
    Astner, S
    Molls, M
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4605 - 4610
  • [5] Antiangiogenic therapies in glioblastoma multiforme
    McNamara, Mairead G.
    Mason, Warren P.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (05) : 643 - 654
  • [6] Prognostic factors in glioblastoma multiforme
    Hulshof, MCCM
    Koot, RW
    Schimmel, EC
    Dekker, F
    Bosch, DA
    González, DG
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (06) : 283 - 290
  • [7] Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses
    Jiang, Cecilia
    Mogilevsky, Casey
    Belal, Zayne
    Kurtz, Goldie
    Alonso-Basanta, Michelle
    Helou, Joelle
    Salgado, Noelia Sanmamed
    CANCERS, 2023, 15 (23)
  • [8] Glioblastoma multiforme
    Welch, Mary
    Lai, Rose
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2009, 11 (04) : 297 - 305
  • [9] Gliomatosis cerebri: evolution to glioblastoma multiforme
    Jimenez Caballero, P. E.
    Mollejo Villanueva, M.
    Marsal Alonso, C.
    NEUROLOGIA, 2007, 22 (06): : 395 - 398
  • [10] ProNGF Expression and Targeting in Glioblastoma Multiforme
    Marsland, Mark
    Dowdell, Amiee
    Faulkner, Sam
    Jobling, Phillip
    Rush, Robert A.
    Gedye, Craig
    Lynam, James
    Griffin, Cassandra P.
    Baker, Mark
    Marsland, Joanne
    Jiang, Chen Chen
    Hondermarck, Hubert
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)